Keith has been in biotechnology since it started and brings many decades of executive experience from various UK and US companies ranging from start-ups to global firms. He worked for GSK and ICI/Zeneca in genetics and molecular biology leading several large groups including Discovery, to finally running Zeneca's patent group. He then joined the West Coast biotech Maxygen, leading the small molecule group through the IPO and growing a business which was spun out as Codexis. On returning to the UK, Keith worked with a fund called BBSF and acted as CEO for several companies in the portfolio, including Spear, sold to Advent International. He led Domainex through a merger with NCE to form a successful business in protein structure-based chemistry. Polytherics was built through organic growth since 2005 to a company of >30 people and is now part of Abzena. Keith is currently chairman of Domainex, and Canbex and has a portfolio of other interests.

Abdul holds the position of Professor of Pharmaceutics at the UCL School of Pharmacy. His research sits at the interface between pharmaceutical science and gastroenterology, forging links between basic science and clinical outcomes. Abdul is an international authority on oral drug delivery and absorption, and has published over 300 papers, book chapters, abstracts, and patents. He leads a large multi-disciplinary research group to further the understanding of gastrointestinal physiology by fundamental research. This knowledge has been translated into the design of new technologies and improved disease treatments, many of which are in late stage clinical trials. Abdul has been the recipient of many prestigious awards in his field and is a frequent speaker at international conferences. He also serves as a consultant to numerous pharmaceutical companies, and is on the advisory boards of healthcare organisations, charitable bodies, and scientific journals.

Vipul’s research expertise encompasses small molecule and biological drug development, with particular knowledge of overcoming the biological barriers in the gastrointestinal tract to achieve oral administration of biopharmaceuticals. He received his Master of Science degree in Drug Delivery at The School of Pharmacy, University of London, where he researched oral peptide delivery. He then pursued a Ph.D. in Pharmaceutics at the UCL School of Pharmacy, where his research was aimed at exploring the biological mechanisms involved in the oral delivery and intestinal uptake of anti-TNF-α monoclonal antibodies.

James is the founder and Executive Chairman of Cycle Pharmaceuticals, a young Cambridge-based company focused on improving existing pharmaceuticals. James was formerly CEO of Archimica, an international contract manufacturing organization of active pharmaceutical ingredients and their pre-cursors for the global branded and generic pharmaceutical industries. Archimica has manufacturing sites in the US, UK, Germany, France, and Italy. During his tenure at Archimica, James recruited and led a new management team, and implemented a detailed strategic repositioning of the business. Archimica was sold to the Euticals group in 2011. Prior to Archimica, James was a Managing Director at TowerBrook Capital Partners and a Partner at Soros Private Equity Partners. James began his career working in the mergers and acquisitions department of Morgan Stanley. James holds a first-class MA and MPhil degrees from the University of Cambridge.